Delcath Systems (NASDAQ:DCTH – Get Free Report) and Cerus (NASDAQ:CERS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.
Profitability
This table compares Delcath Systems and Cerus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | 6.05% | 5.56% | 4.98% |
| Cerus | -3.23% | -10.44% | -3.42% |
Earnings and Valuation
This table compares Delcath Systems and Cerus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $109.96 million | 6.50 | $2.70 million | $0.16 | 128.44 |
| Cerus | $226.57 million | 1.77 | -$15.63 million | ($0.03) | -66.17 |
Delcath Systems has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 5.3% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Delcath Systems and Cerus, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 0 | 1 | 2 | 1 | 3.00 |
| Cerus | 1 | 1 | 3 | 0 | 2.40 |
Delcath Systems currently has a consensus target price of $29.33, indicating a potential upside of 42.74%. Cerus has a consensus target price of $5.25, indicating a potential upside of 164.48%. Given Cerus’ higher possible upside, analysts plainly believe Cerus is more favorable than Delcath Systems.
Risk and Volatility
Delcath Systems has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
Summary
Delcath Systems beats Cerus on 10 of the 15 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.
About Cerus
Cerus Corporation is a biomedical products company focused on improving the safety of blood components used for transfusions. Its primary offering is the INTERCEPT Blood System, which uses a pathogen-reduction process designed to inactivate a broad range of viruses, bacteria, parasites and white blood cells in donated blood components. INTERCEPT is used to process platelet and plasma components. Cerus also develops related processing devices and supplies for blood centers and transfusion services.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
